Estradiol Cypionate

Estrogen Sex Hormone / Estrogen Derivative

Dosage & Administration Guidelines

Species Route Dose Frequency Duration & Clinical Notes
Cattle IM 1-2 mg per animal Single dose Duration: Once
Notes: For induction of estrus, administer at the appropriate stage of the estrous cycle. For pyometra, often used in combination with prostaglandin F2α.
Dog IM 0.5-1 mg per dog Single dose Duration: Once
Notes: Rarely used; may be used for mismating, but not recommended due to risk of bone marrow suppression.
Horse IM 5-10 mg per mare Single dose Duration: Once
Notes: Not commonly used; other estrogens or protocols are preferred.

Clinical Indications & Species Uses

General Indications
  • Estrogen replacement therapy in cases of estrogen deficiency
  • Induction of estrus in livestock
  • Therapeutic management of certain reproductive disorders
Dog (Canine)
  • Treatment of vaginal hyperplasia
  • Mismating (as an abortifacient, though not recommended)
Cattle (Bovine)
  • Induction of estrus in beef and dairy cattle
  • Treatment of pyometra (in combination with prostaglandins)
  • Therapeutic use in cases of retained placenta (though controversial)

Pharmacology & Mechanism of Action

Drug Class: Estrogen | Pharmacological Group: Sex Hormone / Estrogen Derivative

Mechanism of Action: Estradiol cypionate is a long-acting ester of estradiol, the primary estrogenic hormone. It binds to estrogen receptors (ERα and ERβ) in target tissues, leading to receptor activation and modulation of gene transcription. This results in the development and maintenance of female reproductive structures, secondary sexual characteristics, and regulation of the estrous cycle. In males, it can inhibit gonadotropin secretion and produce anti-androgenic effects. It also affects calcium metabolism, bone density, and cardiovascular function.

Pharmacodynamics: Estradiol cypionate produces estrogenic effects similar to endogenous estradiol but with a prolonged duration due to slow release from the injection site. It induces uterine growth, proliferation of the vaginal epithelium, and thickening of the endometrium. It stimulates the release of prolactin and can cause mammary gland development. In cattle, it is used to induce estrus and for therapeutic purposes such as treatment of pyometra. It also has effects on the hypothalamic-pituitary axis, suppressing FSH and LH secretion at high doses.

⚡ Pharmacokinetics Summary

Absorption: After intramuscular injection, estradiol cypionate is slowly absorbed from the injection site due to its ester form, providing a prolonged duration of action. Peak plasma concentrations are reached within 1-3 days.
Distribution: Estradiol is widely distributed throughout the body, with high concentrations in adipose tissue, liver, and reproductive organs. It crosses the placenta and is excreted in milk.
Metabolism: Estradiol is metabolized primarily in the liver via oxidation and conjugation (glucuronidation and sulfation). The cypionate ester is hydrolyzed to release free estradiol.
Excretion: Metabolites are excreted primarily in urine and bile, with some enterohepatic recirculation. Fecal excretion also occurs.
Half-Life: The half-life of estradiol cypionate is approximately 5-7 days in cattle, but the pharmacodynamic effect lasts longer due to slow release.
Bioavailability: Bioavailability is high after intramuscular injection, but oral bioavailability is low due to extensive first-pass metabolism.
Protein Binding: Estradiol is approximately 98% bound to plasma proteins, mainly sex hormone-binding globulin (SHBG) and albumin.

Available Formulations & Strengths

Injectable Solution 2 mg/mL, 5 mg/mL (IM)

Contraindications & Clinical Warnings

Contraindications:
  • Pregnancy (except when used for termination)
  • Known hypersensitivity to estradiol or any component
  • Animals with estrogen-dependent tumors (e.g., mammary tumors)
  • Animals with a history of thromboembolic disease
  • Use in immature animals (unless specifically indicated)
  • Do not use in animals intended for breeding unless specifically directed
Warnings & Clinical Precautions:
  • Use with caution in animals with hepatic or renal impairment
  • May cause bone marrow suppression, especially in dogs, with repeated or high doses
  • May cause cystic endometrial hyperplasia in dogs and cats
  • In cattle, may cause ovarian cysts if used improperly
  • Avoid use in lactating animals unless withdrawal times are observed
  • Use in food animals must comply with regulatory withdrawal periods
  • Wear protective gloves when handling the drug to avoid skin absorption

Adverse Effects & Reactions

Common:

  • Injection site reactions (pain, swelling)
  • Mild transient behavioral changes
  • Altered estrous cycle
  • Mammary gland enlargement

Serious / Severe:

  • Bone marrow suppression (especially in dogs)
  • Aplastic anemia
  • Pyometra or endometritis
  • Ovarian cysts
  • Thromboembolism
  • Hepatotoxicity

Rare:

  • Anaphylaxis
  • Carcinogenesis (long-term use)
  • Feminization in males

Key Drug Interactions

Interacting Drug / Class Clinical Effect & Mechanism Severity
Corticosteroids May enhance the risk of thromboembolism and fluid retention. Moderate
Prostaglandins (e.g., cloprostenol) Synergistic effect for luteolysis and treatment of pyometra. Mild
Hepatic enzyme inducers (e.g., phenobarbital) May increase metabolism of estradiol, reducing efficacy. Moderate
Anticoagulants (e.g., warfarin) Estrogens may alter anticoagulant response; monitor. Moderate

Overdose & Toxicity Management

Signs of Toxicity:

  • Signs of hyperestrogenism: persistent estrus, vulvar swelling, mammary enlargement
  • Bone marrow suppression leading to leukopenia, thrombocytopenia, anemia
  • Gastrointestinal signs (vomiting, diarrhea)
  • In cattle, cystic ovaries and nymphomania

Emergency Treatment Protocol: There is no specific antidote. Treatment is symptomatic and supportive. Discontinue the drug and manage signs. For bone marrow suppression, provide supportive care including antibiotics and blood transfusions if necessary. In severe cases, consider bone marrow stimulants (e.g., filgrastim) but prognosis is guarded.

Food Animal Withdrawal Times

🥩 Meat: 0 days🥛 Milk: 0 days

Estradiol cypionate is not approved for use in food animals in many countries. If used extra-label, follow regulatory guidelines. In the US, no withdrawal times are established for estradiol cypionate; however, a withdrawal period of at least 0 days for meat and milk is often cited, but consult the label and regulatory authorities.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20-25°C (68-77°F), excursions permitted between 15-30°C (59-86°F).

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Protect from light. Keep container tightly closed. Do not freeze.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use; available as a compounded product or for research use.

Extra-Label (Off-Label) Use: In the US, estradiol cypionate is not FDA-approved for veterinary use. Extra-label use in food animals requires a valid veterinary-client-patient relationship and must comply with AMDUCA regulations. Withdrawal times must be established by the veterinarian, and residues must be below tolerance levels.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Estradiol cypionate is a potent estrogen with a prolonged duration of action. Its use in veterinary medicine is limited due to the availability of safer alternatives and the risk of serious adverse effects, particularly bone marrow suppression in dogs. In cattle, it is occasionally used for estrus induction and treatment of pyometra, but its use is controversial and often replaced by prostaglandins and GnRH protocols. Due to its potential for abuse and residues, it is not recommended for routine use in food animals. Always adhere to withdrawal times and regulatory guidelines. In companion animals, consider alternative therapies for conditions like urinary incontinence (e.g., phenylpropanolamine, diethylstilbestrol) due to the risk of aplastic anemia with estrogens.

References & Literature

  • 📚 Plumb's Veterinary Drug Handbook
  • 📚 Papich Veterinary Pharmacology and Therapeutics
  • 📚 Compendium of Veterinary Products (CVP)